S0569

SB 239063

>98% (HPLC)

• Sinónimos: trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole
• Fórmula empírica (notación de Hill): C₂₀H₂₁N₄O₂F
• Número de CAS: 193551-21-2
• Peso molecular: 368.40
• MDL number: MFCD03792786
• UNSPSC Code: 12352200
• PubChem Substance ID: 329824431
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: >98% (HPLC)
• form: powder
• color: white
• mp: 206-207.2 °C
• solubility: DMSO: 11 mg/mL; H₂O: insoluble
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: COc1nccc(n1)-c2c(ncn2[C@@H]3CC[C@@H](O)CC3)-c4ccc(F)cc4
• InChI: 1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16-
• InChI key: ZQUSFAUAYSEREK-WKILWMFISA-N

Descripción

General description

SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.

Application

SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.

Biochem/physiol Actions

Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)